Biotech »

Bellus Health receives U.S. patent for BLU-5937

Bellus Health receives U.S. patent for BLU-5937

Alpha Stox April 24, 2017 Comments Off

Mr. Roberto Bellini reports BELLUS HEALTH ANNOUNCES GRANT OF NEW U.S. PATENT COVERING LEAD COMPOUND FOR CHRONIC COUGH The U.S. Patent and Trademark Office has issued U.S. patent No. 9,598,409, which grants claims covering

Read More »
ProMetic trial to exclude pirfenidone, PBI-4050 combo

ProMetic trial to exclude pirfenidone, PBI-4050 combo

Alpha Stox April 18, 2017 Comments Off

Mr. Pierre Laurin reports FDA CONFIRMS PROMETIC’S PBI-4050 IPF CLINICAL TRIAL DESIGN Prometic Life Sciences Inc. has received concurrence from the U.S. Food and Drug Administration (FDA) on the design of the first of

Read More »
Ventripoint Diagnostics Ltd is Featured on CEO Clips Airing on BNN

Ventripoint Diagnostics Ltd is Featured on CEO Clips Airing on BNN

Alpha Stox March 30, 2017 Comments Off

Toronto, Ontario – March 30, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) is please to announce the Corporation is being featured this week on CEO Clips airing on BNN.  CEO Clips,

Read More »
Ventripoint holders convert all outstanding debentures

Ventripoint holders convert all outstanding debentures

Alpha Stox March 29, 2017 Comments Off

Dr. George Adams reports VENTRIPOINT ANNOUNCES CONVERSION OF ALL OUTSTANDING DEBENTURES AND EXERCISE OF WARRANTS Ventripoint Diagnostics Ltd. is now debt-free, due to the conversion of all outstanding debentures previously issued by the corporation.

Read More »
SQI Diagnostics signs agreement to partner on revolutionary cardiac event prediction test

SQI Diagnostics signs agreement to partner on revolutionary cardiac event prediction test

Alpha Stox March 27, 2017 Comments Off

Toronto, Ontario, March 27, 2017SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”),

Read More »
Ventripoint closes $3.35-million placement

Ventripoint closes $3.35-million placement

Alpha Stox March 24, 2017 Comments Off

Dr. George Adams reports VENTRIPOINT ANNOUNCES CLOSING OF PRIVATE PLACEMENT Ventripoint Diagnostics Ltd. has closed its previously announced non-brokered private placement of 10,496,938 units at 32 cents per unit for total gross proceeds of

Read More »
3D’s TeloView can identify Alzheimer’s patients

3D’s TeloView can identify Alzheimer’s patients

Alpha Stox March 21, 2017 Comments Off

Mr. Hugh Rogers reports 3D SIGNATURES’ TELOVIEW SOFTWARE IDENTIFIES AND STAGES PATIENTS WITH ALZHEIMER’S DISEASE FROM A CHEEK SWAB 3D Signatures Inc. has provided clinical study results which confirm that based on a swab

Read More »
RepliCel’s baldness treatment shown to be safe in trial

RepliCel’s baldness treatment shown to be safe in trial

Alpha Stox March 14, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL’S PHASE 1 CLINICAL TRIAL FOR HAIR LOSS SUCCEEDS IN MEETING PRIMARY ENDPOINTS RepliCel Life Sciences Inc. has successfully completed its first-in-human clinical study of the company’s autologous cell therapy

Read More »
Revive appoints Wang as scientific adviser

Revive appoints Wang as scientific adviser

Alpha Stox March 8, 2017 Comments Off

Mr. Craig Leon reports REVIVE THERAPEUTICS APPOINTS DR. YANLIN WANG, MD, PHD, AS SCIENTIFIC ADVISOR FOR CANNABINOID-BASED THERAPEUTICS TARGETING KIDNEY DISEASE Dr. Yanlin Wang, MD, PhD, will join Revive Therapeutics Ltd. as a scientific

Read More »
RepliCel hires FreeMind to seek research financing

RepliCel hires FreeMind to seek research financing

Alpha Stox March 7, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL PURSUES NON-DILUTING GRANT FUNDING TO ACCELERATE VALUE CREATION AND COMMERCIALIZATION RepliCel Life Sciences Inc. has retained The FreeMind Group, a premier international firm that assists life science organizations in

Read More »
Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1